在这项最新研究中，研究团队进行了体内激酶组 CRISPR 筛选，从中确定了 CDK10 是肿瘤免疫监视的关键抑制因子。 从机制上来说，CDK10 通过磷酸化 DNMT1 和 RAP80 来减少双链 RNA 和 R-loop 的积累，从而减轻由 ...

该公司的生物团队在将创新产品成功推向市场的各个方面拥有150多年的丰富经验，首席医疗和科学官Christine Ginocchio博士是分子诊断学和临床微生物学领域的世界知名专家。她曾是60多项工业和制药临床试验的主要研究者，其中包括21项体外诊断设备研究，获得了美国食品药品管理局 (FDA) 的批准。她的研究将给VedaBio带来技术支撑。

CRISPR has the power to correct genetic mutations, but current delivery methods are either unsafe or inefficient, keeping the technology from reaching its full medical potential. With the power to ...

It acts as a sort of molecular fumigator to battle phages and plasmids. CRISPR-Cas9 has long been likened to a kind of genetic scissors, thanks to its ability to snip out any desired section of DNA ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

CRISPR Therapeutics' stock is down 19% since December, with a slow Casgevy launch and significant R&D investments, yet strong cash reserves provide a safety net. Q4 earnings show no revenue from ...

Sam Berns was my friend. With the wisdom of a sage, he inspired me and many others about how to make the most of life. Afflicted with the rare disease called progeria, his body aged at a rapid rate, ...

The recent approval by the U.S. Food and Drug Administration (FDA) of Casgevy, a therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics that uses CRISPR gene editing to treat patients ...

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...